PolyPeptide Group AG (XSWX:PPGN) Total Inventories: CHF143.9 Mil (As of Dec. 2025)


XSWX:PPGN PolyPeptide Group AG XSWX:PPGN
74 GF Score
Price CHF46.50
GF Value CHF30.72
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Total Inventories?

PolyPeptide Group AG XSWX:PPGN +4.38% 74 Total Inventories is CHF143.9 Mil as of Dec. 2025. GuruFocus rates XSWX:PPGN with a GF Score™ of 74/100 and a GF Value™ of CHF30.72 (Significantly Overvalued). The stock has 9 warning signs investors should review.

PolyPeptide Group AG's total inventories for the quarter that ended in Dec. 2025 was CHF143.9 Mil. PolyPeptide Group AG's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was CHF145.9 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. PolyPeptide Group AG's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was CHF-8.14.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. PolyPeptide Group AG's Days Inventory for the six months ended in Dec. 2025 was 165.89.

Inventory Turnover measures how fast the company turns over its inventory within a year. PolyPeptide Group AG's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.10.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. PolyPeptide Group AG's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.70.

PolyPeptide Group AG  (XSWX:PPGN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

PolyPeptide Group AG's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is

Net-Net Working Capital Per Share (Q: Dec. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(69.602+0.75 * 56.795+0.5 * 143.933-452.909
-0-0)/33.007
=-8.14

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PolyPeptide Group AG's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=145.9145/160.526*365 / 2
=165.89

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

PolyPeptide Group AG's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2025 ) / Average Total Inventories (Q: Dec. 2025 )
=160.526 / 145.9145
=1.10

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PolyPeptide Group AG's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=145.9145 / 209.277
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

PolyPeptide Group AG Total Inventories Related Terms

PolyPeptide Group AG Total Inventories Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Total Inventories Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial 117.60 143.17 121.19 136.64 143.93

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.19 153.95 136.64 147.90 143.93
XSWX:PPGN
74GF Score
PolyPeptide Group AG XSWX:PPGN
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of CHF143.9 Mil mean?
PolyPeptide Group AG (XSWX:PPGN) has a Total Inventories of CHF143.9 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Total Inventories too high?
PolyPeptide Group AG's current Total Inventories is CHF143.9 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Total Inventories compare to ZTS and UTHR?
PolyPeptide Group AG's Total Inventories of CHF143.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Total Inventories is CHF143.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF30.72, compared to a current price of CHF46.50 — trading 51.4% above its estimated fair value. The current Total Inventories is CHF143.9 Mil. PolyPeptide Group AG's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current Total Inventories is CHF143.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF46.50 is trading 51.4% above its estimated GF Value™ of CHF30.72. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for XSWX:PPGN:

  • Total Inventories: CHF143.9 Mil
  • GF Value™: CHF30.72 vs. price of CHF46.50 (51.4% above fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
74GF Score

Get the complete analysis for XSWX:PPGN

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF46.50
Price
CHF30.72
GF Value